Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 7/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026598 | 0.97 | SIGMAR1 (0.53) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL14923973 | 0.95 | SIGMAR1 (0.55) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL10169300 | 0.93 | KMT2A (0.53) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL14923967 | 0.87 | KMT2A (0.51) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL17660589 | 0.87 | L3MBTL1 (0.48) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL24123752 | 0.87 | L3MBTL3 (0.68) | KDM2BL3MBTL3L3MBTL1KMT2AHRH3 | |
| SCHEMBL14924004 | 0.87 | L3MBTL3 (0.73) | KDM2BL3MBTL3L3MBTL1KMT2AHRH3 | |
| SCHEMBL25897977 | 0.86 | HRH3 (0.52) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL23328568 | 0.86 | HRH3 (0.52) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 | |
| SCHEMBL21731334 | 0.86 | KMT2A (0.47) | KDM2BL3MBTL3L3MBTL1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-03-02 | — | — | US | disclosed |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HWANG SUNG YEOUN (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | KDM2B 1072/4885L3MBTL3 4884/4885L3MBTL1 4883/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | KDM2B 2480/4885L3MBTL3 4851/4885L3MBTL1 4514/4885 |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | KDM2B 1072/4885L3MBTL3 4884/4885L3MBTL1 4883/4885 |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | ESRRG, ESR1, ESR2 | KDM2B 1160/4885L3MBTL3 4884/4885L3MBTL1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.